Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) EBITDA (2016 - 2025)

IGC Pharma (IGC) has disclosed EBITDA for 16 consecutive years, with -$1.8 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA fell 6.24% to -$1.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$6.5 million, a 48.44% increase, with the full-year FY2025 number at -$7.2 million, up 45.14% from a year prior.
  • EBITDA was -$1.8 million for Q3 2025 at IGC Pharma, down from -$1.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$1.2 million in Q1 2025 to a low of -$6.7 million in Q1 2022.
  • A 5-year average of -$2.8 million and a median of -$2.4 million in 2024 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: crashed 185.41% in 2021, then skyrocketed 66.85% in 2024.
  • IGC Pharma's EBITDA stood at -$2.3 million in 2021, then fell by 0.26% to -$2.3 million in 2022, then crashed by 141.17% to -$5.6 million in 2023, then surged by 66.85% to -$1.8 million in 2024, then grew by 0.38% to -$1.8 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's EBITDA are -$1.8 million (Q3 2025), -$1.6 million (Q2 2025), and -$1.2 million (Q1 2025).